



## **Med. pract. Stefanie Müller**

Neurologie · Dept. III

### **Kontakt**

Med. pract. Stefanie Müller  
Rorschacherstrasse 95  
9007 St. Gallen  
Switzerland

T +41 71 494 1805  
Stefanie.Mueller@kssg.ch

### **Bereiche**

Neurologie

## Publikationen (43)

Greselin M, Lu P, Melie-Garcia L, Ocampo-Pineda M, Galbusera R, Cagol A, Weigel M, de Oliveira Siebenborn N, Ruberte E, Benkert P, Müller S, Finkener S, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Diepers M, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Gobbi C, Leppert D, Kim O, Cattin P, Hoepner R, Roth P, Kappos L, Kuhle J, Granziera C. Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort. *Bioengineering (Basel)* 2024; 11

Cagol A, Benkert P, Melie-Garcia L, Schaedelin S, Leber S, Tsagkas C, Barakovic M, Galbusera R, Lu P, Weigel M, Ruberte E, Radue E, Yaldizli O, Oechtering J, Lorscheider J, D'Souza M, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Remonda L, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Cattin P, Absinta M, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. *Neurology* 2023; 102:e207768.

Abdelhak A, Benkert P, Schaedelin S, Boscardin W, Cordano C, Oechtering J, Ananth K, Granziera C, Melie-Garcia L, Montes S, Beaudry-Richard A, Achtnichts L, Oertel F, Lalive P, Leppert D, Müller S, Henry R, Pot C, Matthias A, Salmen A, Oksenberg J, Giulio D, Zecca C, D'Souza M, Du Pasquier R, Bridel C, Gobbi C, Kappos L, Hauser S, Cree B, Kuhle J, Green A, UCSF, MS EPIC, and the SMSC Study Teams. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. *JAMA Neurol* 2023

Meier S, Willemse E, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, Cagol A, Barakovic M, Galbusera R, Subramaniam S, Barro C, Abdelhak A, Thebault S, Achtnichts L, Lalive P, Müller S, Pot C, Salmen A, Giulio D, Zecca C, D'Souza M, Orleth A, Khalil M, Buchmann A, Du Pasquier R, Yaldizli O, Derfuss T, Berger K, Hermesdorf M, Wiendl H, Piehl F, Battaglini M, Fischer U, Kappos L, Gobbi C, Granziera C, Bridel C, Leppert D, Maceski A, Benkert P, Kuhle J. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. *JAMA Neurol* 2023; 80:287-297.

Todea A, Melie-Garcia L, Barakovic M, Cagol A, Rahmanzadeh R, Galbusera R, Lu P, Weigel M, Ruberte E, Radue E, Schaedelin S, Benkert P, Oezguer Y, Sinnecker T, Müller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Lalive P, Bridel C, Zecca C, Derfuss T, Remonda L, Wagner F, Vargas M, Du Pasquier R, Pravatà E, Weber J, Gobbi C, Leppert D, Wuerfel J, Kober T, Marechal B, Corredor-Jerez R, Psychogios M, Lieb J, Kappos L, Cuadra M, Kuhle J, Granziera C. A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. *J Magn Reson Imaging* 2023

Achtnichts L, Zecca C, Findling O, Kamm C, Müller S, Kuhle J, Lutterotti A, Gobbi C, Viviani C, Villiger-Borter E, Nedeltchev K. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS). *BMJ Neurol Open* 2023; 5:e000304.

Friedli C, Salmen A, Achtnichts L, Derfuss T, Gobbi C, Kuhle J, Lalive P, Müller S, Papadopoulou A, Pot C, Zecca C, Chan A, Kamm C. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022. *Clinical and Translational Neuroscience* 2022

Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea R, Rahmanzadeh R, Galbusera R, Lu P, Weigel M, Melie-Garcia L, Ruberte E, Siebenborn N, Battaglini M, Radue E, Yaldizli O, Oechtering J, Sinnecker T, Lorscheider J, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Remonda L, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Cattin P, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. *JAMA Neurol* 2022; 79:682-692.

Oechtering J, Lincke T, Schaedelin S, Décard B, Maceski A, Orleth A, Meier S, Willemse E, Buchmann A, Khalil M, Derfuss T, Benkert P, Heijnen I, Regeniter A, Müller S, Achtnichts L, Lalive P, Salmen A, Pot C, Gobbi C, Kappos L, Granziera C, Leppert D, Schlaeger R, Lieb J, Kuhle J, Swiss MS Cohort Study. Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. *Ann Neurol* 2022; 91:814–820.

Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive P, Mueller C, Müller S, Naegelin Y, Oksenberg J, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani M, Granziera C, Piehl F, Leppert D, Kuhle J. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. *Lancet Neurol* 2022; 21:246–257.

Oechtering J, Naegelin Y, Maceski A, Meier S, Berger K, Wiendl H, Lincke T, Lieb J, Yaldizli O, Sinnecker T, Derfuss T, Regeniter A, Zecca C, Gobbi C, Kappos L, Granziera C, Leppert D, Kuhle J, Conen D, Aeschbacher S, Subramaniam S, Schaedelin S, Benkert P, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Fischer-Barnicol B, Orleth A, Chan A, Pot C, Barakovic M, Rahmzadeh R, Galbusera R, Heijnen I, Lalive P, Wuerfel J, Swiss Multiple Sclerosis Cohort Study. Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. *Ann Neurol* 2021; 90:477–489.

Rodgers S, Calabrese P, Ajdacic-Gross V, Steinemann N, Kaufmann M, Salmen A, Manjaly Z, Kesselring J, Kamm C, Kuhle J, Chan A, Gobbi C, Zecca C, Müller S, von Wyl V. Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. *J Psychosom Res* 2021; 144:110402.

Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. *Cancer Immunol Immunother* 2020; 70:563–568.

Kaufmann M, Puhan M, Salmen A, Kamm C, Manjaly Z, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR). 60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. *Front Neurol* 2020; 11:156.

Heckmann J, Todorova M, Müller S, Broser P, Sturm V. First Clinical Experience with Anti-myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis. *Klin Monbl Augenheilkd* 2020

Müller S, Vehoff J. Aktuelle Therapien der Multiplen Sklerose. *der informierte @rzt* 2019; Vol. 9:26–27.

Achtnichts L, Salmen A, Chan A, Czaplinski A, Derfuss T, Du Pasquier R, Findling O, Gobbi C, Zecca C, Müller S, Kamm C, Kuhle J, Lalive P, Martin R, Pot C, Papadopoulou A. Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. *Clinical and Translational Neuroscience* 2019

Barin L, Kamm C, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan M, von Wyl V, Swiss Multiple Sclerosis Registry. How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. *Mult Scler* 2019; 26:489–500.

Kamm C, Muehl S, Mircsof D, Müller S, Czaplinski A, Achtnichts L, Stellmes P, Di Virgilio G. Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey. *Front Neurol* 2018; 9:821.

Puhan M, Steinemann N, Kamm C, Müller S, Kuhle J, Kurmann R, Calabrese P, Kesselring J, von Wyl V, Swiss Multiple Sclerosis Registry Smsr. A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. *Swiss Med Wkly* 2018; 148:w14623.

Uffer D, Müller S, Vehoff J. Multiple Sklerose: Neues zur monoklonalen Antikörpertherapie. InFo Neurologie & Psychiatrie 2018; 1:15-18.

Vehoff J, Hägele-Link S, Humm A, Müller S, Sauter R, Tettenborn B, Hundsberger T (2017). Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial.

Pardini M, Putzki N, Tettenborn B, Valmaggia C, Gass A, Würfel J, Ruberte E, Kuhle J, Vehoff J, Müller S, Botzkowski D, Yaldizli O. The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography. Eur J Neurol 2016

Muehl S, Czaplinski A, Stelmess P, Kamm C, Müller S (2016). Role of family planning in women of child-bearing age with multiple sclerosis (MS) in Switzerland: Results of the Women.

Giulio D, Kamm C, Mattle H, Lotter C, Du Pasquier R, Schlupe M, Pot C, Lalive P, Yaldizli O, Gobbi C, Kappos L, Kuhle J, Louvion J, Derfuss T, Stippich C, Benkert P, Lorscheider J, Müller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue E, Sprenger T, SMSC Scientific Board. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PloS one 2016; 11:e0152347.

Müller S. Behandlung eines Multiple-Sklerose-Schubs - Orale versus intravenöse Steroide. InFo NEUROLOGIE & PSYCHIATRIE 2015; Vol. 14, Nr. 1 2015; Vol. 14:5-5.

Prochnicki A, Zieglgänsberger D, Vehoff J, Müller S, Tettenborn B, Hundsberger T (2015). Glioblastoma multiforme: Chameleon of neurology A case report.

Engeler D, Meyer D, Abt D, Müller S, Schmid H. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol 2015; 15:105.

Pardini M, Putzki N, Tettenborn B, Valmaggia C, Würfel J, Gass A, Kuhle J, Vehoff J, Müller S, Botzkowski D, Yaldizli O (2015). Brain metabolites and retinal nerve fibre layer thickness and their relation to disability in multiple sclerosis: a longitudinal high-field proton magnetic resonance spectroscopy and optical coherence tomography study.

Disanto G, Derfuss T, Louvion J, Kamm C, Mattle H, Lotter C, du Pasquier R, Schlupe M, Pot C, Lalive P, Kappos L, Stippich C, Sprenger T, Benkert P, Lorscheider J, Müller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue E, Kuhle J (2015). The Swiss multiple sclerosis cohort study: a prospective nationwide investigation of disease evolution and the effects of new disease modifying drugs.

Döhler N, Müller S, Vehoff J, Galovic M, Tettenborn B (2014). Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Bortler E, Traber M. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. Eur Neurol 2013; 70:35-41.

Yildiz M, Müller S, Vehoff J, Tettenborn B (2011). Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate: 1 year follow-up.

Vehoff J, Müller S, Tettenborn B. Multiple Sklerose: Neue Diagnosekriterien und neue Therapiemöglichkeiten. InFo Neurologie & Psychiatrie 2011; Vol.9

Hundsberger T, Müller S, Sommacal A, Fretz C, Tettenborn B. Koinzidenz von ischämischer Enzephalopathie und essentieller Thrombozythämie: zerebrale kortikale Venenthrombose ?. S C H W E I Z E R A R C H I V F Ü R N E U R O L O G I E U N D P S Y C H I A T R I E 2010; 161:262-265.

Müller S, Bönig L, Von Manitius S, Weder B, Tettenborn B (2009). Abnormal sleep/wake-patterns in. Präsentiert bei: 173. Tagung der Schweizerischen Neurologischen Gesellschaft in Luzern, -

Vehoff J, Müller S (2009). Spontaneous internal carotid artery dissection presenting as hypoglossal nerve palsy. Präsentiert bei: Gemeinsame Jahrestagung Schweizerische Neurologische Gesellschaft SNG (182. Tagung), Interlaken

Müller S, Endress E, Schött D, Hägele-Link S (2006). Anti-Hu syndrome preceding a carcinoma of the vocal cords. Präsentiert bei: 177. Tagung der Schweizerischen Neurologischen Gesellschaft (Interlaken), -

Müller S, Endress E, Schött D, Hägele-Link S, Tettenborn B (2006). Anti-Hu syndrome preceding a carcinoma of the vocal cords. Präsentiert bei: 177. Tagung Schweiz. Neurologischen Gesellschaft, Interlaken

Müller S, Tettenborn B, Bönig L (2005). Wound botulism in an injection drug user. Präsentiert bei: 176. Tagung der Schweizerischen Neurologischen Gesellschaft (St. Gallen), -

Müller S, Tettenborn B, Schött D, Altland K (2004). Hereditary transthyretin amyloidosis: a case report of a newly described TTR variant Ile 107Met. Präsentiert bei: 172. Tagung der Schweizerischen Neurologischen Gesellschaft (Interlaken), 172. Tagung der Schweizerischen Neurologischen Gesellschaft (Interlaken)

Müller S, Schött D, Altland K, Tettenborn B. Hereditary transthyretin amyloidosis: a case report of a newly described TTR variant Ile 107 Met. Schweiz Arch Neurol Psych 2004; 155:91-92.

Müller S, Schött D, Altland K, Tettenborn B (2003). Hereditary transthyretin amyloidosis: a case report of a newly described TTR variant Ile 107 Met. Präsentiert bei: Joint Meeting of the Swiss Society for Neurology (SNG) and the Swiss Society for Sleep Research, Sleep Medicine and Chronobiology (SGSSC), Zürich

## Projekte (15)

**Funktionelle Evaluation des autonomen Nervensystems im Zusammenhang mit der erstmaligen Einnahme von 0,5mg Fingolimod (Gilenya®) bei Patienten mit schubförmig verlaufender Multipler Sklerose**

*Klinische Forschung - 21.08.2013 - 18.06.2015*

*Abgeschlossen*

**Swiss Multiple Sclerosis Cohort-Study (SMSC-Study): A Prospective Swiss wide Investigation of Key Phases in Disease Evolution and new Treatment options**

*Klinische Forschung - 01.01.2013 - 30.11.2022*

*Automatisch geschlossen*

**Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy - FTY720**

*Klinische Forschung - 20.05.2012 - 31.12.2018*

*Automatisch geschlossen*

**An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™**

*Klinische Forschung - 01.04.2012 - 01.04.2013*

*Abgeschlossen*

**A 32-week, patient- and rater-blinded, randomized, multicenter, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from previous treatment with natalizumab to fingolimod (FTY720)**

*Klinische Forschung - 01.04.2012 - 01.12.2012*

*Abgebrochen*

**Tenere Extension: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis**

*Klinische Forschung - 01.05.2011 - 31.12.2013*

*Abgeschlossen*

**A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis**

*Klinische Forschung - 01.04.2011 - 28.02.2012*

*Abgeschlossen*

**Cohort Study comparing Corpus Callosum Atrophy as a marker of later development of cognitive impairment in patients with early and relapsing multiple sclerosis**

*Klinische Forschung - 14.03.2011 - 31.05.2011*

*Abgeschlossen*

**Neurocognitive changes in patients with relapsing multiple sclerosis treated with Natalizumab**

*Klinische Forschung - 01.01.2011 - 31.12.2012*

*Abgeschlossen*

**A dose blind, multicenter, extension study to determine the safety and efficacy of 2 doses of BG00012 monotherapy with Relapsing Remitting Multiple Sclerosis**

*Klinische Forschung - 01.12.2010 - 08.12.2020*

*Automatisch geschlossen*

**A 4 Month, open label, multi-center study to explore the tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis**

*Klinische Forschung - 01.10.2010 - 31.05.2011*

*Abgeschlossen*

**Substudie zu SOLAR: Untersuchung der Wirkung einer Vitamin D-Substitution auf die T-Lymphozyten bei Patienten mit schubförmig-remittierender MS unter Behandlung mit Rebif®, EMR 200136-532**

*Klinische Forschung - 01.07.2010 - 31.12.2013*

*Abgeschlossen*

**Tenere: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis**

*Klinische Forschung - 03.05.2010 - 30.06.2011*

*Abgeschlossen*

**Selective S1P1 receptor agonist in Patients with Relapsing-Remitting Multiple Sclerosis**

*Klinische Forschung - 01.11.2009 - 01.11.2010*

*Abgeschlossen*

**A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate (BG00012) in Subjects with Relapsing-Remitting Multiple Sclerosis**

*Klinische Forschung - 01.10.2008 - 01.12.2010*

*Abgeschlossen*